We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+4.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.7B
AUM Growth
-$252M
(-13%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-9.43%
Top 10 Holdings %
Top 10 Hldgs %
40.6%
Holding
107
New
9
Increased
39
Reduced
24
Closed
6
Top Buys
| 1 |
MMED
MiniMed Group Inc
MMED
|
+$17.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$15M |
| 3 |
Boston Scientific
BSX
|
+$9.3M |
| 4 |
HTFL
Heartflow Inc
HTFL
|
+$8M |
| 5 |
PTC Therapeutics
PTCT
|
+$7.08M |
Top Sells
| 1 |
EXAS
Exact Sciences
EXAS
|
+$61.1M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$45.3M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$27.4M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$24M |
| 5 |
Travere Therapeutics
TVTX
|
+$21.9M |
Sector Composition
| 1 | Healthcare | 99.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$39.3B
| $118M | 6.93% |
1,209,465
-125,805
| -9% | -$12.7M |
|
2
Eli Lilly
LLY
$1.03T
| $90.8M | 5.35% |
98,700
-6,700
| -6% | -$6.79M |
|
|
3
Madrigal Pharmaceuticals
MDGL
$12.4B
| $89.5M | 5.28% |
170,999
+31,381
| +22% | +$15M |
|
4
Mirum Pharmaceuticals
MIRM
$7.37B
| $74.9M | 4.42% |
811,294
+49,000
| +6% | +$4.61M |
|
5
argenx
ARGX
$53.4B
| $71.9M | 4.24% |
98,500
-4,750
| -5% | -$3.72M |
|
6
Rhythm Pharmaceuticals
RYTM
$7.54B
| $60M | 3.54% |
689,748
-5,262
| -0.8% | -$512K |
|
7
Insmed
INSM
$23.9B
| $51.4M | 3.03% |
314,300
-4,950
| -2% | -$761K |
|
8
Ascendis Pharma A/S
ASND
$17.4B
| $44.4M | 2.62% |
194,000
-9,500
| -5% | -$2.13M |
|
9
Xenon Pharmaceuticals
XENE
$6.51B
| $44.4M | 2.62% |
763,020
-24,768
| -3% | -$1.14M |
|
|
10
Travere Therapeutics
TVTX
$5.31B
| $43.9M | 2.59% |
1,477,954
-732,368
| -33% | -$21.9M |
|
11
Kymera Therapeutics
KYMR
$9.22B
| $41.4M | 2.44% |
496,871
| – | – |
|
12
Penumbra
PEN
$12.4B
| $39.6M | 2.33% |
120,500
| – | – |
|
13
Intuitive Surgical
ISRG
$134B
| $37.8M | 2.23% |
82,000
| – | – |
|
14
Scholar Rock
SRRK
$6.44B
| $36.4M | 2.14% |
739,816
+6,339
| +0.9% | +$284K |
|
15
Enliven Therapeutics
ELVN
$3.7B
| $32.4M | 1.91% |
826,500
+28,095
| +4% | +$778K |
|
|
16
Boston Scientific
BSX
$63.4B
| $32.3M | 1.91% |
515,300
+116,250
| +29% | +$9.3M |
|
17
iRhythm Holdings
IRTC
$3.7B
| $30.9M | 1.82% |
261,750
+26,750
| +11% | +$3.86M |
|
18
Structure Therapeutics
GPCR
$3.6B
| $30.9M | 1.82% |
640,217
-108,019
| -14% | -$7.39M |
|
19
Agios Pharmaceuticals
AGIO
$2.37B
| $27M | 1.59% |
799,163
| – | – |
|
20
Ultragenyx Pharmaceutical
RARE
$3.15B
| $25.5M | 1.5% |
1,218,773
-48,468
| -4% | -$1.09M |
|
21
Alnylam Pharmaceuticals
ALNY
$37.6B
| $24.5M | 1.44% |
74,000
+2,750
| +4% | +$936K |
|
22
Cogent Biosciences
COGT
$6.58B
| $24M | 1.42% |
624,155
-224,875
| -26% | -$8.3M |
|
23
Tenet Healthcare
THC
$15.8B
| $23.6M | 1.39% |
125,000
| – | – |
|
24
DexCom
DXCM
$28.6B
| $22.3M | 1.32% |
355,600
+8,300
| +2% | +$578K |
|
25
Celldex Therapeutics
CLDX
$3B
| $20.6M | 1.22% |
650,270
-42,268
| -6% | -$1.15M |
|
Similar funds
AAM
SGI
WAS
SI
PP
SWM
AAA
FDP